Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NKT2152 |
Synonyms | |
Therapy Description |
NKT2152 binds to HIF2A and blocks DNA binding, potentially resulting in decreased target gene expression, reduced tumor cell proliferation and tumor growth inhibiton (Cancer Res 2022;82(12_Suppl):Abstract nr 6330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NKT2152 | NKT-2152|NKT 2152 | HIF2A Inhibitor 6 | NKT2152 binds to HIF2A and blocks DNA binding, potentially resulting in decreased target gene expression, reduced tumor cell proliferation and tumor growth inhibiton (Cancer Res 2022;82(12_Suppl):Abstract nr 6330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05119335 | Phase Ib/II | NKT2152 | A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |